Evermay Wealth Management LLC Has $233,000 Holdings in Celgene Corporation (CELG)

Evermay Wealth Management LLC maintained its stake in Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,793 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Evermay Wealth Management LLC’s holdings in Celgene Corporation were worth $233,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of CELG. Neuberger Berman Group LLC increased its stake in Celgene Corporation by 4.0% in the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after buying an additional 71,729 shares during the last quarter. Lincoln Capital Corp increased its stake in Celgene Corporation by 0.6% in the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after buying an additional 185 shares during the last quarter. Swiss National Bank increased its stake in Celgene Corporation by 27.2% in the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after buying an additional 588,000 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Celgene Corporation by 9.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after buying an additional 54,210 shares during the last quarter. Finally, Iguana Healthcare Management LLC increased its stake in Celgene Corporation by 12.5% in the 1st quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $11,199,000 after buying an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 79.36% of the company’s stock.

Several equities research analysts have issued reports on CELG shares. Morgan Stanley lowered shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research note on Thursday. Leerink Swann upgraded shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $94.42 to $150.00 in a research note on Friday, June 16th. They noted that the move was a valuation call. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research note on Monday, June 26th. Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a research note on Monday, August 28th. Finally, BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and lifted their price target for the company from $96.93 to $131.70 in a research note on Friday, June 30th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and twenty-two have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $150.60.

Celgene Corporation (NASDAQ:CELG) opened at 139.21 on Monday. The stock’s 50 day moving average is $139.31 and its 200 day moving average is $129.53. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $147.17. The firm has a market capitalization of $108.91 billion, a price-to-earnings ratio of 43.11 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.44 earnings per share. Analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

In related news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares in the company, valued at $9,061,220.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,233 shares of company stock valued at $6,268,259. 0.95% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Evermay Wealth Management LLC Has $233,000 Holdings in Celgene Corporation (CELG)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2017/10/09/evermay-wealth-management-llc-has-233000-holdings-in-celgene-corporation-celg.html.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply